Rational approach to migraine attacks relief
https://doi.org/10.14412/2074-2711-2025-2-100-106
Abstract
Strategies against migraine attacks include the use of pharmacological agents that are both non-specific and specific for migraine. Despite the wide arsenal of pharmacological agents, effective pain relief is achieved in only one third of migraine patients. When choosing the optimal analgesics for each patient, several key characteristics of the drug should be considered: not only its analgesic effect, but also its ability to rapidly terminate concomitant symptoms without the need for additional analgesics. One of the justified strategies is the combination of specific and nonspecific agents or the use of ready-made combination preparations that allow a multimodal effect in migraine.
About the Author
G. R. Tabeeva
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Department of Nervous Diseases and Neurosurgery, Institute of Professional Education, N.V. Sklifosovsky Institute of Clinical Medicine
11, Rossolimo St., Build. 1, Moscow 119021
Competing Interests:
The article is sponsored by Bosnalijek JSC. The conflict of interests did not affect the results of the study. The author is solely responsible for submitting the final version of the manuscript for publication. The author has participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by the author.
References
1. Ashina M. Migraine. N Engl J Med. 2020 Nov 5;383(19):1866-76. doi: 10.1056/NEJMra1915327
2. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-80. doi: 10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14.
3. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202
4. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992 Aug;12(4):221-8; discussion 186. doi: 10.1046/j.1468-2982.1992.1204221.x
5. Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. Headache. 2018 May;58 Suppl 1:4-16. doi: 10.1111/head.13300
6. Dodick DW. Migraine. Lancet. 2018 Mar 31;391(10127):1315-30. doi: 10.1016/S0140-6736(18)30478-1. Epub 2018 Mar 6.
7. Tepper SJ. History and Review of antiCalcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache. 2018 Nov;58 Suppl 3:238-75. doi: 10.1111/head.13379. Epub 2018 Sep 22.
8. Tabeeva GR, Filatova EG, Amelin AV, et al. Alternative and complementary treatments for migraine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1):4-15. doi: 10.14412/2074-2711-2024-1-4-15 (In Russ.).
9. Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14. doi: 10.1038/s41582-021-00509-5. Epub 2021 Jun 18.
10. Katsarava Z, Mania M, Lampl C, et al. Poor medical care for people with migraine in Europe – evidence from the Eurolight study. J Headache Pain. 2018 Feb 1;19(1):10. doi: 10.1186/s10194-018-0839-1
11. Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. Lancet. 2021 Apr 17;397(10283):1485-95. doi: 10.1016/S0140-6736(20)32160-7. Epub 2021 Mar 25.
12. American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019 Jan;59(1):1-18. doi: 10.1111/head.13456. Epub 2018 Dec 10. Erratum in: Headache. 2019 Apr;59(4):650-1. doi: 10.1111/head.13506
13. Bentivegna E, Onan D, Martelletti P. Unmet Needs in Preventive Treatment of Migraine. Neurol Ther. 2023 Apr;12(2):337-42. doi: 10.1007/s40120-023-00438-z.Epub 2023 Feb 4.
14. Bentivegna E, Galastri S, Onan D, Martelletti P. Unmet Needs in the Acute Treatment of Migraine. Adv Ther. 2024 Jan;41(1):1-13. doi: 10.1007/s12325-023-02650-7. Epub 2023 Nov 9.
15. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020 Oct;180:114147. doi: 10.1016/j.bcp.2020.114147. Epub 2020 Jul 10.
16. Bigal ME, Golden W, Buse D, et al. Triptan use as a function of cardiovascular risk. A population-based study. Headache. 2010 Feb;50(2):256-63. doi: 10.1111/j.1526-4610.2009.01595.x. Epub 2009 Dec 21.
17. Lipton RB, Serrano D, Holland S, et al. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache. 2013 Jan;53(1):81-92. doi: 10.1111/j.1526-4610.2012.02265.x. Epub 2012 Oct 18.
18. Dodick DW, Loder EW, Manack Adams A, et al. Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2016 May;56(5):821-34. doi: 10.1111/head.12774. Epub 2016 May 3.
19. Urtecho M, Wagner B, Wang Z, et al. A qualitative evidence synthesis of patient perspectives on migraine treatment features and outcomes. Headache. 2023 Feb;63(2):185-201. doi: 10.1111/head.14430. Epub 2023 Jan 5.
20. Lipton RB, Stewart WF, Stone AM, et al; Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA. 2000 Nov 22-29;284(20):2599-605. doi: 10.1001/jama.284.20.2599
21. Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013 Sep;40(5 Suppl 3):S1-S80.
22. Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics. 2002;20(2):91-100. doi: 10.2165/00019053-200220020-00002
23. Zobdeh F, Ben Kraiem A, Attwood MM, et al. Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol. 2021 Dec;178(23):4588-607. doi: 10.1111/bph.15657. Epub 2021 Sep 26.
24. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia. 2008 Aug;28(8):877-86. doi: 10.1111/j.1468-2982.2008.01578.x. Epub 2008 May 5.
25. Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs. 2010 Aug 20;70(12):1505-18. doi: 10.2165/11537990-000000000-00000
26. Dodick D, Lipton RB, Martin V, et al; Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004 May;44(5):414-25. doi: 10.1111/j.1526-4610.2004.04078.x
27. Tabeeva GR, Amelin AV, Akhmadeeva LR, et al. Optimization of migraine attacks relief. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):126-33. doi: 10.14412/2074-2711-2023-2-126-133 (In Russ.).
28. Tfelt-Hansen P, Pascual J, Ramadan N, et al; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012 Jan;32(1):6-38. doi: 10.1177/0333102411417901
29. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499
30. Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache. 2007 Sep;47(8):1152-68. doi: 10.1111/j.1526-4610.2007.00849.x
31. Tabeeva GR, Kharitonova AA. Gastric stasis in migraine and the efficacy of antimigraine drugs. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1S):4-11. doi: 10.14412/2074-2711-2024-1S-4-11 (In Russ.).
32. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache. 1997;37 Suppl 1:S15-25.
33. Shafqat R, Flores-Montanez Y, Delbono V, Nahas SJ. Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations. J Pain Res. 2020 Apr 30;13:859-64. doi: 10.2147/JPR.S203650
34. Tepper SJ. Orally inhaled dihydroergotamine: a review. Headache. 2013 Sep;53 Suppl 2:43-53. doi: 10.1111/head.12184
35. Ahn AH. On the temporal relationship between throbbing migraine pain and arterial pulse. Headache. 2010 Oct;50(9):1507-10. doi: 10.1111/j.1526-4610.2010.01765.x
36. Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Proc Staff Meet Mayo Clin. 1945;20:241-8.
37. Tabeeva GR, Kosivtsova OV, Kovalchuk NA, Orlyuk TA. Refractory migraine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(2):76-86. doi: 10.14412/2074-2711-2024-2-76-86 (In Russ.).
38. Silberstein SD, Kori SH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013 May;27(5):385-94. doi: 10.1007/s40263-013-0061-2
39. Baron EP, Tepper SJ. Revisiting the role of ergots in the treatment of migraine and headache. Headache. 2010 Sep;50(8):1353-61. doi: 10.1111/j.1526-4610.2010.01662.x. Epub 2010 Mar 29.
40. VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69. doi: 10.1001/jama.2021.7939
41. Bosnalijek DOO, Product composition. Product monograph Nomigren, Bosnalijek, Sarajevo, 2007, 1-2. Available at: http://www.bosnalijek.com/productsL2e?c=zn&zn=NOMIGREN (accessed 30.01.2018).
42. Demaagd G. The pharmacological management of migraine, part 1: overview and abortive therapy. P T. 2008 Jul;33(7):404-16.
43. Miljkovic S, Smajlovic D, Tiric Campara M, et al. The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura. Hippokratia. 2018 Jan-Mar;22(1):17-22.
Review
For citations:
Tabeeva GR. Rational approach to migraine attacks relief. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(2):100-106. (In Russ.) https://doi.org/10.14412/2074-2711-2025-2-100-106
Views:
54
Email this article 